| Market Capitalization (Millions $) |
961 |
| Shares
Outstanding (Millions) |
174 |
| Employees |
234 |
| Revenues (TTM) (Millions $) |
76 |
| Net Income (TTM) (Millions $) |
-31 |
| Cash Flow (TTM) (Millions $) |
16 |
| Capital Exp. (TTM) (Millions $) |
0 |
Optinose Inc
Optinose Inc is a pharmaceutical company that specializes in developing and commercializing innovative treatments for patients with various medical conditions. The company focuses on utilizing its proprietary Optinose Exhalation Delivery System (EDS) technology, which delivers drugs through the nose, to maximize drug delivery and improve patient outcomes.
Optinose's EDS technology enables targeted drug delivery to specific areas of the nasal cavity and sinuses, potentially providing more effective treatment options for conditions such as chronic rhinosinusitis, nasal polyps, and migraines. By delivering drugs directly to the site of action, the company aims to minimize systemic side effects and enhance therapeutic benefits.
Through its research and development efforts, Optinose has developed a pipeline of potential treatments, including its flagship product, XHANCE, for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE has been approved by the United States Food and Drug Administration (FDA) and is commercially available in the United States.
Overall, Optinose Inc strives to leverage its innovative EDS technology to improve patient's lives by providing targeted and effective treatments for various medical conditions affecting the nasal cavity and sinuses.
Company Address: 777 Township Line Road Yardley 19067 PA
Company Phone Number: 364-3500 Stock Exchange / Ticker: NASDAQ OPTN
|
0.000%
1.43% 